These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 15743347)

  • 1. Gambling with gastroesophageal reflux disease: should we worry about the QALY?
    Moayyedi P; Talley NJ
    Am J Gastroenterol; 2005 Mar; 100(3):534-6. PubMed ID: 15743347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of sevelamer in patients with end-stage renal disease.
    Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
    Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic reflections on proton pump inhibitor therapy for non-erosive reflux disease.
    Moayyedi P
    Digestion; 2008; 78 Suppl 1():61-9. PubMed ID: 18832842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Equity weights in the allocation of health care: the rank-dependent QALY model.
    Bleichrodt H; Diecidue E; Quiggin J
    J Health Econ; 2004 Jan; 23(1):157-71. PubMed ID: 15154692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?
    Braithwaite RS; Meltzer DO; King JT; Leslie D; Roberts MS
    Med Care; 2008 Apr; 46(4):349-56. PubMed ID: 18362813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is self-care a cost-effective use of resources? Evidence from a randomized trial in inflammatory bowel disease.
    Richardson G; Sculpher M; Kennedy A; Nelson E; Reeves D; Roberts C; Robinson A; Rogers A; Thompson D
    J Health Serv Res Policy; 2006 Oct; 11(4):225-30. PubMed ID: 17018196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of the Expert Patients Programme (EPP) for patients with chronic conditions.
    Richardson G; Kennedy A; Reeves D; Bower P; Lee V; Middleton E; Gardner C; Gately C; Rogers A
    J Epidemiol Community Health; 2008 Apr; 62(4):361-7. PubMed ID: 18339831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia.
    Breitscheidel L
    J Med Econ; 2008; 11(4):571-84. PubMed ID: 19450068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
    Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
    Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation.
    King JT; Tsevat J; Lave JR; Roberts MS
    Med Decis Making; 2005; 25(6):667-77. PubMed ID: 16282217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Community or patient preferences for cost-effectiveness of cardiac rehabilitation: does it matter?
    Oldridge N; Furlong W; Perkins A; Feeny D; Torrance GW
    Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):608-15. PubMed ID: 18800005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of interventions for problem drinking and alcohol dependence: cost per QALY estimates.
    Mortimer D; Segal L
    Alcohol Alcohol; 2005; 40(6):549-55. PubMed ID: 16103034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality-adjusted life years: how useful in medico economic studies.
    Brauer CA; Neumann PJ
    Fundam Clin Pharmacol; 2005 Dec; 19(6):603-7. PubMed ID: 16313271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of a disease management programme for secondary prevention of coronary heart disease and heart failure in primary care.
    Turner DA; Paul S; Stone MA; Juarez-Garcia A; Squire I; Khunti K
    Heart; 2008 Dec; 94(12):1601-6. PubMed ID: 18450843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The cost per year of life gained: trends and internal contradictions].
    Smulders YM; Thijs A
    Ned Tijdschr Geneeskd; 2006 Nov; 150(45):2467-70. PubMed ID: 17137090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A value-based medicine cost-utility analysis of idiopathic epiretinal membrane surgery.
    Gupta OP; Brown GC; Brown MM
    Am J Ophthalmol; 2008 May; 145(5):923-8. PubMed ID: 18329000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of a randomized trial comparing Helicobacter pylori test-and-treat and prompt endoscopy strategies for managing dyspepsia in a primary-care setting.
    Klok RM; Arents NL; de Vries R; Thijs JC; Brouwers JR; Kleibeuker JH; Postma MJ
    Clin Ther; 2005 Oct; 27(10):1647-57. PubMed ID: 16330302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cost-utility analysis of chronic spinal pain treatment outcomes: converting SF-36 data into quality-adjusted life years.
    Hatten AL; Gatchel RJ; Polatin PB; Stowell AW
    Clin J Pain; 2006 Oct; 22(8):700-11. PubMed ID: 16988566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shoulder acute pain in primary health care: is retraining GPs effective? The SAPPHIRE randomized trial: a cost-effectiveness analysis.
    McKenna C; Bojke L; Manca A; Adebajo A; Dickson J; Helliwell P; Morton V; Russell I; Torgerson D; Watson J
    Rheumatology (Oxford); 2009 May; 48(5):558-63. PubMed ID: 19258378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.